Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms

作者：Gleitz Helene F E; Liao Ai Yin; Cook James R; Rowlston Samuel F; Forte Gabriella M A; D'Souza Zelpha; O'Leary Claire; Holley Rebecca J; Bigger Brian W^*

来源：EMBO Molecular Medicine, 2018, 10(7): UNSP e8730.

DOI：10.15252/emmm.201708730

• apolipoprotein E
• blood-brain barrier
• Hunter
• mucopolysaccharidosis type II
• stem cell gene therapy

The pediatric lysosomal storage disorder mucopolysaccharidosis type II is caused by mutations in IDS, resulting in accumulation of heparan and dermatan sulfate, causing severe neurodegeneration, skeletal disease, and cardiorespiratory disease. Most patients manifest with cognitive symptoms, which cannot be treated with enzyme replacement therapy, as native IDS does not cross the blood-brain barrier. We tested a brain-targeted hematopoietic stem cell gene therapy approach using lentiviral IDS fused to ApoEII (IDS.ApoEII) compared to a lentivirus expressing normal IDS or a normal bone marrow transplant. In mucopolysaccharidosis II mice, all treatments corrected peripheral disease, but only IDS.ApoEII mediated complete normalization of brain pathology and behavior, providing significantly enhanced correction compared to IDS. A normal bone marrow transplant achieved no brain correction. Whilst corrected macrophages traffic to the brain, secreting IDS/IDS.ApoEII enzyme for cross-correction, IDS.ApoEII was additionally more active in plasma and was taken up and transcytosed across brain endothelia significantly better than IDS via both heparan sulfate/ApoE-dependent receptors and mannose-6-phosphate receptors. Brain-targeted hematopoietic stem cell gene therapy provides a promising therapy for MPS II patients.

• 出版日期2018-7